Status:
COMPLETED
Treatment of Zollinger-Ellison Syndrome
Lead Sponsor:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Conditions:
Zollinger Ellison Syndrome
Eligibility:
All Genders
18+ years
Brief Summary
In patients with Zollinger-Ellison Syndrome the level of gastric acid is elevated. This increased level of gastric acid is what causes the symptoms of the disease. Certain types of medication can cont...
Detailed Description
This protocol describes the use of histamine H2-receptor antagonists to control gastric acid hypersecretion in patients with Zollinger-Ellison syndrome. It details which patients will be considered fo...
Eligibility Criteria
- INCLUSION CRITERIA:
Basal gastric acid secretion of greater than 15 mEq/hr (normal less than 10) or greater than 5 mEq/hr if they have had a previous gastric resection, a fasting plasma concentration of immunoreactive gastrin of greater than 100 pg/ml (normal less than 100), a positive secretin provocative tests or histological diagnosis of gastrinoma.
Key Trial Info
Start Date :
January 27 1989
Trial Type :
OBSERVATIONAL
End Date :
December 10 2007
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00001241
Start Date
January 27 1989
End Date
December 10 2007
Last Update
July 2 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States, 20892